Half-year report · HY
2503.TEDINET S100YV8N
Period2026-01-01 → 2026-06-30
Filed2026-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.22T | 2026-01-01 → 2026-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.43T | 2025-01-01 → 2025-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.14T | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥129.0bn | 2026-01-01 → 2026-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥68.7bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥150.9bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥237.9bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥83.8bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥101.7bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥147.5bn | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥52.8bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥116.1bn | 2026-01-01 → 2026-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥60.5bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.40T | at 2026-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.49T | at 2025-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.30T | at 2025-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.72T | at 2026-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.90T | at 2025-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.68T | at 2026-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.60T | at 2025-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.41T | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.53T | at 2024-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥1.36T | at 2026-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.29T | at 2025-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.12T | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥168.1bn | at 2026-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥125.3bn | at 2025-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥132.4bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥118.6bn | at 2024-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥137.3bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥295.4bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥67.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥53.7bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥185.0bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥61.6bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥162.5bn | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥110.5bn | 2025-01-01 → 2025-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥35.8bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥126.33 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥182.13 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥65.23 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥182.13 | 2025-01-01 → 2025-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥65.22 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 40.0% | at 2026-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.8% | at 2025-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 34.0% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2026-01-01 → 2026-06-30 | ¥46.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2026-01-01 → 2026-06-30 | ¥12.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥33.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2026-01-01 → 2026-06-30 | −¥1.5bn |
| Reconciling Itemsreconciling | revenue | 2026-01-01 → 2026-06-30 | −¥38.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2026-01-01 → 2026-06-30 | −¥38.9bn |
| Reconciling Itemsreconciling | segment profit | 2026-01-01 → 2026-06-30 | −¥34.2bn |
| Alcoholic Beveragesreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥519.1bn |
| Alcoholic Beveragesreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥517.8bn |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥1.3bn |
| Alcoholic Beveragesreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥62.1bn |
| Health Sciencereportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥131.1bn |
| Health Sciencereportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥128.8bn |
| Health Sciencereportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥2.3bn |
| Health Sciencereportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥10.4bn |
| Non Alcoholic Beveragesreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥296.7bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥294.9bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥1.8bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥31.0bn |
| Pharmaceuticalsreportable segment | revenue | 2026-01-01 → 2026-06-30 | ¥263.6bn |
| Pharmaceuticalsreportable segment | revenue external | 2026-01-01 → 2026-06-30 | ¥263.5bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2026-01-01 → 2026-06-30 | ¥139m |
| Pharmaceuticalsreportable segment | segment profit | 2026-01-01 → 2026-06-30 | ¥60.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥47.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥14.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥32.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | −¥591m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥38.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥38.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥30.0bn |
| Alcoholic Beveragesreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥493.8bn |
| Alcoholic Beveragesreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥492.6bn |
| Alcoholic Beveragesreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.2bn |
| Alcoholic Beveragesreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥53.2bn |
| Health Sciencereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥129.7bn |
| Health Sciencereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥127.2bn |
| Health Sciencereportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| Health Sciencereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥8.6bn |
| Non Alcoholic Beveragesreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥273.4bn |
| Non Alcoholic Beveragesreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥271.8bn |
| Non Alcoholic Beveragesreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.6bn |
| Non Alcoholic Beveragesreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥29.5bn |
| Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥230.7bn |
| Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥230.5bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥156m |
| Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥33.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 869
| Item | Context | Value | Unit |
|---|---|---|---|
| Intersegment revenue IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 32889000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration_ReconcilingItemsMember | -38291000000 | JPY |
| Intersegment revenue IFRS | Prior1InterimDuration | － | JPY |
| Revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 493787000000 | JPY |
| Revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 273403000000 | JPY |
| Revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 230654000000 | JPY |
| Revenue IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 129736000000 | JPY |
| Revenue IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 47021000000 | JPY |
| Revenue IFRS | Prior1InterimDuration_ReconcilingItemsMember | -38291000000 | JPY |
| Revenue IFRS | Prior1InterimDuration | 1136309000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 53162000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 29537000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 33503000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 8615000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -591000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration_ReconcilingItemsMember | -29981000000 | JPY |
| Segment profit loss IFRS | Prior1InterimDuration | 94245000000 | JPY |
| Other operating income IFRS | Prior1InterimDuration | 2135000000 | JPY |
| Other operating expenses IFRS | Prior1InterimDuration | 27658000000 | JPY |
| Finance income IFRS | Prior1InterimDuration | 4644000000 | JPY |
| Finance costs IFRS | Prior1InterimDuration | 8998000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1InterimDuration | 19392000000 | JPY |
| Profit loss before tax IFRS | Prior1InterimDuration | 83761000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 517844000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 294884000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 263489000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 128843000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 12816000000 | JPY |
| Revenue from external customers IFRS | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | InterimDuration | 1217876000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 1267000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 1789000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 139000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 2260000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 33440000000 | JPY |
| Intersegment revenue IFRS | InterimDuration_ReconcilingItemsMember | -38896000000 | JPY |
| Intersegment revenue IFRS | InterimDuration | － | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 519111000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 296673000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 263629000000 | JPY |
| Revenue IFRS | InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 131103000000 | JPY |
| Revenue IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 46256000000 | JPY |
| Revenue IFRS | InterimDuration_ReconcilingItemsMember | -38896000000 | JPY |
| Revenue IFRS | InterimDuration | 1217876000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00395-000AlcoholicBeveragesReportableSegmentMember | 62094000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00395-000NonAlcoholicBeveragesReportableSegmentMember | 30965000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00395-000PharmaceuticalsReportableSegmentMember | 60540000000 | JPY |
| Segment profit loss IFRS | InterimDuration_jpcrp040300-ssr_E00395-000HealthScienceReportableSegmentMember | 10403000000 | JPY |
| Segment profit loss IFRS | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -1475000000 | JPY |
| Segment profit loss IFRS | InterimDuration_ReconcilingItemsMember | -34225000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |